Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil

Pedroso, Juan Carlos Montano; Garcia, Élvio Bueno; Moraes, Mariana Alcântara Rodrigues de; Veiga, Daniela Francescato; Ferreira, Lydia Masako

doi:10.1016/s2352-3026(18)30071-1

Cited by 11 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Correcting underlying nutritional deficiencies is important in decreasing the frequency of complications, which can occur with body‐contouring surgery . For example, since iron‐deficiency anemias, which may be found in patients after bariatric surgery, could complicate a body‐contouring procedure, the use of IV iron therapy may be needed . While the overall complication rate of body contouring after bariatric surgery is high, the majority of such complications are considered minor .…”

Section: Executive Summarymentioning

confidence: 99%

Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists

Mechanick

Apovian

Brethauer

et al. 2020

Obesity

324

464

View full text Add to dashboard Cite

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Methods Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. Results New or updated topics in this CPG include: contextualization in an adiposity‐based chronic disease complications‐centric model, nuance‐based and algorithm/checklist‐assisted clinical decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health care arena. There are 85 numbered recommendations that have updated supporting evidence, of which 61 are revised and 12 are new. Noting that there can be multiple recommendation statements within a single numbered recommendation, there are 31 (13%) Grade A, 42 (17%) Grade B, 72 (29%) Grade C, and 101 (41%) Grade D recommendations. There are 858 citations, of which 81 (9.4%) are evidence level (EL) 1 (highest), 562 (65.5%) are EL 2, 72 (8.4%) are EL 3, and 143 (16.7%) are EL 4 (lowest). Conclusions Bariatric procedures remain a safe and effective intervention for higher‐risk patients with obesity. Clinical decision‐making should be evidence based within the context of a chronic disease. A team approach to perioperative care is mandatory, with special attention to nutritional and metabolic issues.

show abstract

Section: Executive Summarymentioning

confidence: 99%

Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists

Mechanick

Apovian

Brethauer

et al. 2020

Obesity

324

464

View full text Add to dashboard Cite

show abstract

“…Seventy-four RCTs were multicenter, and studies were performed in a wide range of clinical settings (Table 1). The most common settings were obstetrics (39 RCTs; 9993 participants), 31,32,[37][38][39]49,50,53,55,56,63,64,73,74,76,79,81,83,88,91,[95][96][97]104,105,111,[129][130][131]140,148,152,157,160,167,172,174,177,182 surgery (27 RCTs; 4223 participants), 54,57,58,61,80,89,99,[101][102][103]107,109,111,[126][127][128]…”

Section: Study Characteristicsmentioning

confidence: 99%

“…RCTs 41,45,46,51,54,58,67,70,72,103,104,108,111,113,120,[125][126][127][128][129]137,139,145,147,151,159,163,167,170,180 and high for 106 RCTs.…”

Section: Risk Of Biasmentioning

confidence: 99%

“…The high risk of bias was most frequently attributable to insufficient blinding of participants, study personnel, or outcome assessors or not providing sufficient information for a decision. A total of 88 included studies [31][32][33][35][36][37]40,42,43,[45][46][47]49,50,52,54,56,59,62-66,69-71,73-75,77,78,82,85-88,92,94-97, [99][100][101]103,110,111,113,[116][117][118][119][120][122][123][124][125][126]131,132,135,137,141,142,147,150,153,[155][156][157][158][159][161][162][163][169][170][171]174,179,…”

Section: Twenty-twomentioning

confidence: 99%

See 1 more Smart Citation

Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

“…The safety profile is therefore well established in many different patient groups, including CKD, GI disorders, women’s health disorders, oncology, cardiology, and for patient blood management (Tables 2 , 3 , 4 , 5 , 6 , 7 ). To date, more than 50 published clinical studies, covering numerous patient populations, have reported safety outcomes with administration of iron sucrose; 18 of these studies have been reported in the last 5 years [ 40 , 46 , 47 , 50 , 52 , 53 , 58 , 66 , 73 , 74 , 111 , 113 , 114 , 126 , 127 , 129 – 131 ].…”

Section: Safety and Tolerability Of Iron Sucrosementioning

confidence: 99%

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

et al. 2020

View full text Add to dashboard Cite

Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient populations, this can be treated effectively with oral iron supplementation; but in patients who are unable to take or who do not respond to oral iron therapy, intravenous iron administration is recommended. Furthermore, in certain conditions, such as end-stage kidney disease, chronic heart failure, and inflammatory bowel disease, intravenous iron administration has become first-line treatment. One of the first available intravenous iron preparations is iron sucrose (Venofer ® ), a nanomedicine that has been used clinically since 1949. Treatment with iron sucrose is particularly beneficial owing to its ability to rapidly increase hemoglobin, ferritin, and transferrin saturation levels, with an acceptable safety profile. Recently, important new data relating to the use of iron sucrose, including the findings from the landmark PIVOTAL trial in patients with end-stage kidney disease, have been reported. Several years ago, a number of iron sucrose similars became available, although there have been concerns about the clinical appropriateness of substituting the original iron sucrose with an iron sucrose similar because of differences in efficacy and safety. This is a result of the complex and unique physicochemical properties of nanomedicines such as iron sucrose, which make copying the molecule difficult and problematic. In this review, we summarize the evidence accumulated during 70 years of clinical experience with iron sucrose in terms of efficacy, safety, and cost-effectiveness.

show abstract

Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil

Cited by 11 publications

References 37 publications

Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-Analysis

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Contact Info

Product

Resources

About